Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer

Mini Rev Med Chem. 2004 Jan;4(1):61-8. doi: 10.2174/1389557043487510.

Abstract

The favourable nuclear properties of copper-67 and rhenium-188 for therapeutic application are described, together with methods for the chemical synthesis of a number of derivatives. Survival from invasive bladder cancer has changed little over the past 20 years. The intravesicular administration of Cu-67 or Re-188 radiopharmaceuticals in the treatment of bladder cancer offers some promise for improvement in this situation.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / metabolism
  • Copper Radioisotopes / chemistry
  • Copper Radioisotopes / pharmacokinetics
  • Copper Radioisotopes / therapeutic use*
  • Humans
  • Immunoconjugates / therapeutic use
  • Isomerism
  • Mucin-1 / metabolism
  • Radioimmunodetection
  • Radioimmunotherapy
  • Radioisotopes / chemistry
  • Radioisotopes / pharmacokinetics
  • Radioisotopes / therapeutic use*
  • Radiopharmaceuticals / therapeutic use*
  • Rhenium / chemistry
  • Rhenium / pharmacokinetics
  • Rhenium / therapeutic use*
  • Urinary Bladder Neoplasms / diagnosis
  • Urinary Bladder Neoplasms / radiotherapy*

Substances

  • Biomarkers, Tumor
  • Copper Radioisotopes
  • Immunoconjugates
  • Mucin-1
  • Radioisotopes
  • Radiopharmaceuticals
  • Rhenium